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Abstract
A series of half-sandwich arene-ruthenium complexes of the type [(η6-p-cymene) Ru
(thiosemicarbazone)Cl]+ have been synthesized and their biological activity investigated. The first
structurally characterized arene-ruthenium half-sandwich complex with a thiosemicarbazone ligand
is reported.
Introduction
Thiosemicarbazones are of considerable pharmacological interest since a number of
derivatives have shown a broad spectrum of chemotherapeutic properties. The wide range of
biological activities possessed by substituted thiosemicarbazones and their metal complexes
include cytotoxic, antitumor, antibacterial and antiviral properties. This is particularly true for
the heterocyclic thiosemicarbazones [1]. It has been suggested that the antitumor activity of
heterocyclic thiosemicarbazones is due to the compounds modifying the reductive conversion
of ribonucleotides to deoxyribonucleotides as a result of the inhibition of the ribonucleotide
reductase enzyme which inhibits DNA synthesis [2]. The ligands coordinate to metal ions
inside the cell, forming complexes which supposedly act as the true active species. The
biological properties of the ligands can be modified and in fact enhanced, by the linkage to
metal ions [3,4].
Metal complexes are used in many fields of drug discovery. Platinum coordination compounds
are widely used as antitumor drugs. The first platinum antitumor drug introduced in the clinic
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were cis-diamminedichloroplatinum(II) (cisplatin) and it has become the most widely used
anticancer drug in the world. The clinical efficacy of cisplatin and other platinum drugs is
diminished by intrinsic and acquired tumor resistance. In addition cisplatin has high toxicity,
leading to side effects which limit the administered dose [5]. These limiting issues has led to
an intense effort to design new transition metal-based compounds that are capable of
overcoming problems associated with cisplatin while maintaining the same level of activity
and broadening the spectrum of the therapeutic effect. In attempts to find a new, metal-based
anticancer drug with activity complementary to cisplatin, several ruthenium complexes have
recently been investigated for their antitumor activity. Very recently, two ruthenium-(III)
complexes have also successfully completed phase I clinical trials, namely, NAMI-A [6–8]
{NAMI-A, (ImH)[trans-Ru(III)Cl4Im(Me2SO)]; Im - imidazole}, and KP1019 indazolium
trans-[tetrachlorobis(1H-indazole) ruthenate(III)] [9,10].
Organometallic half-sandwich ruthenium(II)-arene complexes are currently attracting
increasing interest as anticancer compounds. Recently developed ruthenium(II) complexes of
the type [(η6-arene)Ru(en)Cl][PF6] (en = ethylenediamine) show promising anticancer activity
[11]. These monofunctional Ru(II) arene complexes have been considered novel antitumor
agents with a mechanism of action different from that of NAMI-A or KP1019. While DNA
binding is believed to be the mechanism of action, other factors such as cell uptake will affect
the cytotoxic activity and is dependent on the nature, particularly the size, of the arene [11,
12]. In addition, they were found to be active toward cisplatin-resistant cells [13,14].
In this paper we report on a study (synthesis, characterization and cytotoxicity) of a series of
half-sandwich organometallic ruthenium complexes containing thiosemicarbazones as the
chelating ligand.
Results and Discussion
Syntheses and characterization
Complex 1 was synthesized in 54% yield by refluxing [(η6-p-cymene)RuCl2]2 [15] with the
ligand [16] in a 2:1 mole ratio in methanol followed by addition of NH4PF6. The solid was
recrystallized from CH2Cl2and ether (Scheme 1). Complexes 2 and 3 were synthesized by
reacting [(η6-p-cymene) RuCl2]2 with the ligand in CH2Cl2 at room temperature, concentrating
the reaction solution and adding ether to precipitate the product (Scheme 1). The reaction
produced red or orange solids that are insoluble in alcohols and water but are very soluble in
acetone, CH2Cl2 and DMSO. For complex 2, crystals suitable for structure determination were
grown by slow diffusion of ether into a CH2Cl2 solution of the complex.
NMR spectral studies
The NMR spectra of the complexes were run in DMSO-d6 as they are very soluble in this
solvent. Similar to other p-cymene complexes, 1 and 3 show a loss of the two-fold symmetry
of the p-cymene ligand [17] upon coordination of the thiosemicarbazone ligand. This is
evidenced by four sets of doublets for the aromatic hydrogen on the p-cymene ligand found
between 6.27 – 6.52 ppm for 1 and 5.95 – 6.02 ppm for 3 [18]. Additionally in 3, the methyl
groups of the isopropyl moiety are inequivalent, observed as two singlets at 1.17 and 1.27 ppm.
The aromatic protons of the thiosemicarbazone ligand show up between 7.57 and 8.50 ppm,
similar to the free ligands. The hydrazinic proton shifts slightly on binding and the imine
(HC=N) proton shifts downfield by as much as 0.15 ppm upon coordination.
Infrared spectra
Thiosemicarbazones exhibit characteristic bands corresponding to various groups in specific
energy regions. The most significant IR bands in the region 4000 – 500 cm−1 are found between
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3150 – 3450 (assigned to NH stretching vibrations); 1580 – 1625 (assigned to C=N + NH);
and ~ 820 – 900 (assigned to C=S vibration). The characteristic absorption peaks of all
complexes are similar. There are three or two bands in the ν(N-H) region and these signals
play an important role in evaluating the nature of the bonding in thiosemicarbazone complexes.
The presence of a band corresponding to hydrazinic N(2)-H group, suggests the coordination
of a thiosemicarbazone to the metal center in a neutral form, while its absence, is suggestive
of deprotonation in the complexes. In all the complexes, there is a band at ~3200 – 3130
cm−1 which is assigned to the hydrazinic N(2)-H group and this support the thione formulation
of the ligand in the complexes. The other band(s) (at ~ 3450 – 3350 cm−1) are the stretching
vibrations of the terminal amino N(3)-H group and do not shift significantly on complexation;
the shift is due to change in the electron density upon complexation of the thiocarbonyl sulfur.
In the complexes the medium intensity band ascribed to υ(C=N) are shifted by up to 25
cm−1 to lower energy upon complexation. This negative shift indicates that the azomethine
nitrogen (N(1)) coordinates to the metal [19,20]. The involvement of the thiocarbonyl group
can similarly be inferred from the wavenumber shifts that occur on binding. The band in the
free ligand at ~840 cm−1 which we attribute to the C=S group shifts to lower frequencies by 5
– 25 cm−1. The size of the shifts suggest that the ligand coordinates as a neutral, bidentate
(through the azomethine nitrogen and thiocarbonyl sulfur) ligand in all the complexes.
Crystal Structure
Crystallogaphic data for 2·CH2Cl2 are given in Table 1. This represents the first example of a
structurally characterized half-sandwich ruthenium arene complex with a thiosemicarbazone
ligand. The molecular structure of cation 2 (Fig. 1) adopts the archetypical piano-stool
geometry of ruthenium half-sandwich arene complexes. The metal is coordinated by the p-
cymene, a terminal chloride and the chelating thiosemicarbazone ligand. The relevant bond
lengths and selected bond angles are given in Table 2. The metal center has essentially
octahedral coordination geometry with some distortion. The Ru–Cl, Ru–S and Ru–N are
comparable to other structurally characterized ruthenium are complexes with similar N-S donor
ligands (unpublished work). Hamaker [21] have reported a series of complexes with an imine-
thioether donor set, [(η6-p-cymene) RuCl(MeSC6H4-2-N=CH-C6H4-p-X]+; these complexes
have Ru–N bond lengths ranging from 2.099 – 2.132 Å, Ru–Cl bond lengths from 2.3978 –
2,4227 Å and Ru–S from 2.3397 – 2.3496 Å. Our values of 2.1452(6) Å, 2.4169(17) Å and
2.3547(6) Å are only slightly longer. The bond angles through ruthenium involving the three
legs of the piano-stool are in the range of 82–86° indicating a distortion from a regular
octahedron (90°). The average Ru–Carene bond of 2.215 Å is in line with other ruthenium arene
half-sandwich complexes [22] and the Ru-centroid distance is 1.699 Å which is similar to our
unpublished compounds and close to the values reported by the Hamaker group. The p-cymene
ligand is somewhat asymmetrically coordinated to the ruthenium. The Ru(1)–C(6) and Ru(1)–
C(7) bonds (average 2.258 Å) are somewhat longer than the Ru(1)–C(8) and Ru(1)–C(9) pair
(average 2.175 Å). Among the other pair, Ru(1)–C(4) and Ru(1)–C(5 have different lengths.
All this leads to a twist in the arene ligand at C(4), possibly to limit any steric interaction
between C(1) methyl of the isopropyl group and the S(1) of the thiosemicarbazone ligand.
Electrochemistry
The electrochemical (cyclic voltammetry) behavior of the complexes has been studied in
dichloromethane using a scan rate of 100 mV/s and tetrabutylammonium hexafluorophosphate
as the supporting electrolyte. The complexes showed similar features in the investigated sweep
range (0 – 2.0 V). There is one irreversible oxidation wave (Fig. 2) corresponding to the Ru
(II)/Ru(III) couple: relative to the Fc/Fc+, Epa was 1024, 1042, 1106 mV for complexes 1, 2
and 3 respectively. There is also an ill-defined oxidation wave at higher potential (near 1700
mV) that becomes more defined as the scan rate increased. As far as we know there are no
reports of electrochemical studies on half-sandwich ruthenium arene complexes with
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thiosemicarbazones. So another comparison with the Hamaker [21] complexes (Epa 1180 –
1336), suggest that with the thione as opposed to the thioether group, the ruthenium center is
more easily oxidized.
Interaction of complexes with ct-DNA
In biological systems, complexes will encounter an array of biomolecules with which they
could potentially react. Hence, it is important to gain a detailed understanding of such
interactions. Since DNA is the primary target of the classical platinum anticancer drugs,
binding studies of ruthenium(II) arene complexes with this molecule is important. It is
recognized that the nature of the arene group affects the mode of binding of these complexes
to DNA. It has been reported that for a series of complexes, [(η6-arene)Ru(en)(Cl)]+
intercalation or groove binding is the principal mode of interaction when the arene is biphenyl
or anthracene derivatives, group that possess flat extended aromatic rings [23]. The mode was
different for the p-cymene derivative. In order to investigate the interaction mode between the
complexes and ct-DNA, the ethidium bromide (EB) fluorescence displacement experiment
was also employed. EB emits intense fluorescent light in the presence of DNA due to its strong
intercalation between the adjacent DNA base pairs. The displacement technique is based on
the decrease of this fluorescence resulting from the displacement of EB from a DNA sequence
by a quencher. The quenching is due to the reduction of the number of binding sites on the
DNA that is available to the EB. The method therefore provides indirect evidence for an
intercalative binding mode. The extent of fluorescence quenching may also be used to
determine the extent of binding between the quencher and DNA. Complex 1 was used to
illustrate this concept. On titration of the EB-DNA solution with 1, there is reduction in the
fluorescence intensity at λem = 600 nm as the [Ru] increases. The spectra show no significant
changes in shape or wavelength. This clearly indicates that some EB molecules are displaced
from their DNA binding sites and replaced by the complex and it is fair to conclude that some
intercalation has occurred. A quantitative estimation of quenching can be obtained from a
Stern-Volmer analysis of the data. According to the Stern-Volmer equation (1) [24], the relative
fluorescence is directly proportional to the concentration of the quencher:
(1)
where F0 and F are the fluorescence emission intensities of the EB-DNA system before and
after the addition of the complexes, KSV is the Stern-Volmer quenching constant and [Q] is
the concentration of the quencher (1). The quenching constants, calculated from the slope of
the Stern-Volmer plot (F0/F vs [Q]) shown in Fig. 3, were found to be 3.73 ×103 M−1 and 2.17
× 103 M−1 at 298 K and 303 K, respectively. The linearity of the quenching plots illustrate that
the quenching is in good agreement with the Stern-Volmer equation. The linearity also indicates
that only one type of quenching process is in operation. It is well known that quenching occurs
through a static (involving the formation of quencher-fluorophore complex) or dynamic
process. High temperatures tend to disrupt ground state complex formation. This fact can be
used to establish which mechanism is in operation. The value of the Stern-Volmer quenching
constant should decrease with an increase in temperature as the ground state complex becomes
less stable. The reverse will be observed for dynamic quenching. The values obtained illustrates
that quenching by the complex is predominantly static. A bimolecular quenching constant
(Kq) can be calculated from the Stern-Volmer constant: KSV = Kqτ0, where τ0 is the lifetime
of the fluorophore and is 22 ns [25]. For 1 Kq is at least an order of magnitude larger than the
limiting value of 1010 M−1 s−1 [24], considered the largest possible value in aqueous medium.
This confirms that the fluorescence quenching is not the result of dynamic quenching, but rather
a consequence of static quenching.
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Viscometric studies
As a means for further clarifying the binding of the complexes with DNA, the viscosity of
DNA solutions containing varying amount of added complex were measured. Photophysical
probes such as absorption or fluorescence measurements generally provide significant but
inconclusive evidence to support an intercalative binding model. Among the common methods,
hydrodynamic methods (viscometry in particular) that are sensitive to DNA length changes
are the most definitive tests of the classical intercalation model of binding in solution. Besides
the ability to unwind DNA, a classical intercalator will cause an increase in the viscosity of a
DNA solution since the DNA helix must lengthen as base pairs are separated to accommodate
the binding ligand [26]. According to theory of Cohen and Eisenberg [27] viscosity data were
plotted as (η/η0)1/3 versus the binding ratio ([Ru]/[DNA]) as shown in Fig. 4. For all the
complexes, it was observed that increasing the complex concentration led to a general increase
in the viscosity of the DNA solution. Thus together with the results from the EB displacement
experiments, we may conclude that the complexes are intercalators. A look at the structure for
2 shows that the p-cymene moiety is incapable of intercalation into DNA as the isopropyl
subgroup deviates significantly out of the plane. In addition the π-electrons are used in bonding
to ruthenium. So it is clear that the flat aromatic portion of the thiosemicarbazone ligand is
responsible for the intercalation.
Cytotoxicity studies
Compounds 1 – 3 were evaluated for their cytotoxicity in a panel of human tumor cell lines -
MCF-7 and MDA-MB-231 (breast adenocarcinoma) as well as HCT 116 and HT-29 (colorectal
carcinoma) - by means of a colorimetric assay (MTS assay) which measures mitochondrial
dehydrogenase activity as an indication of cell viability. The effects of the compounds on the
viability of these cells were evaluated after an exposure period of 72 h. All the complexes
showed moderate cytotoxic potencies and their IC50 values, corresponding to inhibition of
cancer cell growth at the 50% level, are listed in Table 3. As a general observation, complex
2 is the most active against all the cell lines. Also the alkyl group on N(3) is non-innocent as
there appears to be an decrease in potency as the alkyl group gets bigger. Between cell lines
there is also another clearly discernible trend in that the compounds showed higher activities
against the MDA-MB-231 cells, which are estrogen receptor negative (ER(−)) versus the ER
(+) MCF-7 cells. There is a similar trend present in the colon cell lines – activity is higher in
the HCT-116 cells which normally does not express cyclooxygenase COX-2.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
The project described was supported by NIH Grant Number P20 RR-1646 from the IDeA Networks of Biomedical
Research Excellence (INBRE) Program of the National Center of Research Resources.
Appendix A. Supplementary material
CCDC 733807 contains supplementary crystallographic data for 2. These data can be obtained
free of charge from the Cambridge Crystallographic Data Center via
http://www.ccdc.com.ac.uk/data_request/cif
References
1. Klayman DL, Scovill JP, Bartosevich JF, Bruce J. J. Med.Chem 1983;26:39. [PubMed: 6827527]
Beckford et al. Page 5
Inorg Chem Commun. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2. Kovala-Demertzi D, Demertzis MA, Miller JR, Papadopoulou C, Dodorou C, Filousis G. J. Inorg.
Biochem 2001;86:555. [PubMed: 11566327]
3. Garcia-Tojal J, Garcia-Orad A, Serra JL, Pizarro JL, Lezamma L, Arriortua MI, Rojo T. J. Inorg.
Biochem 1999;75:45. [PubMed: 10402676]
4. Petering DH. Bioinorg. Chem 1972;1:255.
5. (a) Chu G. J. Biol. Chem 1994;269:787–790. [PubMed: 8288625] (b) Fuertes MA, Alonso C, Perez
JM. Chem. Rev 2003;103:645–662. [PubMed: 12630848] (c) Agarwal R, Kaye SB. Nat. Rev. Cancer
2003;3:502–516. [PubMed: 12835670]
6. Sava G, Bergamo A. Int. J. Oncol 2000;17:353–365. [PubMed: 10891547]
7. Rademaker-Lakhai JM, Van den Bongard D, Pluim D, Beijnen JH, Schellens JH. Clin. Cancer Res
2004;10:3717–3727. [PubMed: 15173078]
8. (a) Sava G, Gagliardi R, Bergamo A, Alessio E, Mestroni G. Anticancer Res 1999;19:969–972.
[PubMed: 10368640] (b) Bergamo A, Gava B, Alessio E, Mestroni G, Serli B, Cocchieto M, Zorzet
S, Sava G. Int. J. Oncol 2002;21:1331–1338. [PubMed: 12429985] (c) Groessl M, Reisner E, Hartinger
CG, Eichinger R, Semenova O, Timerbaev AR, Jakupec MA, Arion VB, Keppler BK. J. Med. Chem
2007;50:2185–2193. [PubMed: 17402720]
9. (a) Hartinger CG, Zorbas-Seifried S, Jakupec MA, Kynast B, Zorbas H, Keppler BK. J. Inorg. Biochem
2006;100:894–904. (b) Kapitza S, Pongratz M, Jakupec MA, Heffeter P, Berger W, Lackinger L,
Keppler BK, Marian B. J. Cancer Res. Clin. Oncol 2005;131:101–110. [PubMed: 15503135] (c)
Keppler BK, Henn M, Juhl UM, Berger MR, Niebl R, Wagner FE. Prog. Clin. Biochem. Med
1989;10:41–69. (d) Pongratz M, Schluga P, Jakupec MA, Arion VB, Hartinger CG, Allmaier G,
Keppler BK. J. Anal. At. Spectrom 2004;19:46–51.
10. Kreuser ED, Keppler BK, Berdel WE, Piest A, Thiel E. Semin. Oncol 1992;19:73–81. [PubMed:
1373006]
11. Morris RE, Aird RE, Murdoch P, del S, Chen H, Cummings J, Hughes ND, Parsons S, Parkin A,
Boyd G, Jodrell DI, Sadler PJ. J. Med. Chem 2001;44:3616–3621. [PubMed: 11606126]
12. Novakova O, Kasparkova J, Bursova V, Hofr C, Vojtiskova M, Chen H, Sadler PJ, Brabec V. Chem.
Biol 2005;12:121–129. [PubMed: 15664521]
13. Aird RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, Sadler PJ, Jodrell DI. Br. J. Cancer
2002;86:1652–1657. [PubMed: 12085218]
14. Guichard SM, Else R, Reid E, Zeitlin B, Aird R, Muir M, Dodds M, Fiebig H, Sadler PJ, Jodrell DI.
Biochem. Pharmacol 2006;71:408–415. [PubMed: 16360645]
15. Bennett MA, Smith AK. Dalton Trans 1974:233.
16. Beckford FA, Holt A. Journal of Undergraduate Chemistry Research 2007;6:173. Briefly, equimolar
amounts of 9-anthraldehyde and the appropriate N4 alkyl-substituted thiosemicarbazide were
suspended in anhydrous ethanol containing a few drops of glacial acetic acid. The reaction mixture
was heated at reflux for 3½ h and after cooling the light precipitate that formed was collected by
filtration and washed thoroughly with ethanol followed by ether and dried in the vacuum.
17. Moldes I, de la Encarnación E, Roo J, Alvarez-Larena Á, Pinella JF. J. Organomet. Chem
1998;566:165.
18. Hamaker CG, Halbach DP. J. Organomet. Chem 2006;691:3349.
19. Beraldo H, Nacif WF, Teixeria LR, Reboucas JS. Tansition Met. Chem 2002;27:85.
20. West DX, Swearigen JK, Valdee-Martinez J, Hernandez-Ortegs S, El-Sawaf AK, van Meurs F,
Castineiras A, Garcia I, Bermejo E. Polyhedron 1999;18:2919.
21. Hamaker CG, Halbach DP. Polyhedron 2009;28:2228.
22. Allen FA. Acta Crystallogr. Sect. B 2002;58:380. [PubMed: 12037359]
23. Novakova O, Chen H, Vrana O, Rodger A, Sadler PJ, Brabec V. Biochemistry 2003;42:11544.
[PubMed: 14516206]
24. Lacowicz, JR. Principles of Fluorescence Spectroscopy. 3rd Ed.. New York: Springer; 2006.
25. Ghosh KS, Sahoo BK, Jana D, Dasgupta S. J. Inorg, Biochem 2008;102:1711. [PubMed: 18541305]
26. Long EC, Barton JK. Acc. Chem. Res 1990;23:271–273.
27. Cohen G, Eisenberg H. Biopolymers 1969;8:45–55.
Beckford et al. Page 6
Inorg Chem Commun. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1.
Molecular structure of complex 1 with hydrogen atoms omitted for clarity
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Fig. 2.
Cyclic voltammograms for 1 (1 × 10−3 M) measured in CH2Cl2 (vs Ag/AgCl) at various scan
rates
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Fig. 3.
(a) Fluorescence quenching curves (b) Stern-Volmer plot of the ct-DNA-bound ethidium
bromide with 1 at 303 K
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Fig. 4.
Effect of the increasing amount of 1 on the relative viscosity of ct-DNA at 306 (±0.1) K; [DNA]
= 0.1 mM
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Scheme 1.
Synthesis of [(η6-p-cymene)Ru(R-ATSC)Cl]X; X = Cl−, PF6−
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Table 1
Selected crystallographic and refinement data for 2·CH2Cl2
Parameter Value
Empirical formula C28H31Cl4N3SRu
Formula weight 684.49
T (K) 100(2) K
Wavelength (Å) 0.71073 Å
Crystal system Triclinic
Space group P−1
a (Å) 10.492(2)
b (Å) 11.546(2)
c (Å) 12.835(3)
α (deg) 82.230(5)
β (deg) 76.541(5)
γ (deg) 77.429(5)
Volume (Å3) 1470.0(5)
Z 2
Densitycalc (Mg/m3) 1.546
Absorption coefficient (mm−1) 0.991
Crystal size (mm3) 0.37 × 0.26 × 0.05
θ range 1.64 – 26.00
Index ranges −12 ≤ h ≤ 12, −14 ≤ k ≤ 12, −15 ≤ l ≤ 12
No. reflections collected 23578
No. independent reflections 5727[R(int) = 0.0221]
Absorption correction SADABS
Data/rest/param 5727 / 0 / 334
GOF F2 1.059
Final R indices; [I > 2σ(I)] R1 = 0.0252; wR2 = 0.0679
R indices (all data) R1 = 0.0269; wR2 = 0.0688
CCDC 733807
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Table 2
Selected bond lengths [Å] and angles [°] for 2·CH2Cl2
Ru(1)-C(4) 2.218(2) Ru(1)-Cl(1) 2.4169(6)
Ru(1)-C(5) 2.205(2) Ru(1)-N(1) 2.1453(17)
Ru(1)-C(6) 2.259(2) Ru(1)-S(1) 2.3547(6)
Ru(1)-C(7) 2.257(2) N(1)-Ru(1)-S(1) 81.83(5)
Ru(1)-C(8) 2.179(2) N(1)-Ru(1)-Cl(1) 81.66(5)
Ru(1)-C(9) 2.170(2) S(1)-Ru(1)-Cl(1) 86.37(2)
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Table 3
Antiproliferative activity of complexes 1–3 in panel of four human cancer cell lines
IC50 (µM)a
Compound MDA-MB-231 MCF-7 HCT 116 HT-29
1 5.04 ± 0.99 39.2 ± 8.1 9.34 ± 1.08 8.32 ± 3.08
2 2.67 ± 0.38 13.2 ± 0.25 3.27 ± 0.40 4.94 ± 0.50
3 9.01 ± 3.52 18.05 ± 11.8 12.3 ± 0.06 17.4 ± 6.39
Cisplatin 730 506 ± 86 3.10 24.3
a
50% inhibitory concentration after exposure for 72 h in the MTS assay. Values are means ± standard deviations.
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